# Bioequivalence Study of BAY77-1931 Granule

> **NCT01053676** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 59 (actual)

## Conditions studied

- Hyperphosphatemia

## Interventions

- **DRUG:** Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule
- **DRUG:** Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet

## Key facts

- **NCT ID:** NCT01053676
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2014-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01053676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01053676, "Bioequivalence Study of BAY77-1931 Granule". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01053676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*